Monoclonal Antibodies - Information for Providers
Casirivimab/imdevimab and bamlanivimab/etesevimab were granted emergency use authorization for the treatment of mild to moderate COVID-19. Until the national supply of these monoclonal antibodies (mAbs) is sufficient, the Iowa Department of Public Health and the United States government will help facilitate allocation across Iowa.
Find a COVID-19 Monoclonal Antibody Provider
Request COVID-19 Monoclonal Antibodies
Casirivimab/imdevimab and bamlanivimab/etesevimab are available at no cost to healthcare providers. Healthcare providers can submit a request to the Iowa Department of Public Health. This request will be added to a list of eligible recipients for monoclonal antibody products for future allocations. Eligibility is not a guarentee for receiving future allocations of monoclonal antibody products.
Additional information on the distribution process can be found here.
Bebtelovimab (Eli Lilly)
For questions, please contact Combat COVID Monoclonal Antibodies Call Center at 877-332-6585.